Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784924 · ClinicalTrials.gov registry record
EDRN Prostate MRI Biomarker Study
A clinical trial of Prostate Cancer and PSA, sponsored by University of Michigan.
- Recruiting
- Registry status
- 950
- Enrollment target
- 1
- Study location
NCT03784924: Recruiting study of Prostate Cancer and PSA, sponsored by University of Michigan.
NCT03784924 is a study of Prostate Cancer and PSA that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 950 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03784924, a study of Prostate Cancer and PSA, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 950 participants
- Enrollment target
- 1
- Study location
Study Summary
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
Primary Outcome
Pathologic diagnosis of prostate cancer with at least Gleason 7 or worse cancer grade on a needle biopsy
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI prostate
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2028-12-31 |
What NCT03784924 shows while recruiting
NCT03784924 is an observational study that tracks outcomes without assigning an intervention. The registered 950 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (57% higher).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI prostate is the first listed.
NCT03784924 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03784924 about?
NCT03784924 is a clinical study titled "EDRN Prostate MRI Biomarker Study". The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow in...
What is the current status of trial NCT03784924?
This trial is currently recruiting. The enrollment target is 950 participants. The study started on 2019-02-04. Estimated completion is 2028-12-31.
What conditions does trial NCT03784924 study?
This clinical trial studies the following conditions: Prostate Cancer, PSA.
What interventions are being tested in trial NCT03784924?
The interventions under investigation include: MRI prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03784924?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784924 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03784924's enrollment target sits among peer trials
950 70th of 735 higher than 666 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI